Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication

Back to Jobs

SAN DIEGO , Feb. 25, 2022 (GLOBE NEWSWIRE) — Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it will host a virtual Investor R&D Event from 10 a.m. – Noon ET on March 22, 2022 .

Apply Now